The Response of Prostate Cancers to Androgen Deprivation Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 2 August 2024 | Viewed by 3196
Special Issue Editor
Special Issue Information
Dear Colleagues,
Most human prostate cancers are curable by surgery or radiation therapy, or are so slow-growing and occur so late in life that the cancer does not affect lifespan. However, 10–20% of cases progress or recur following curative therapies. Thus, given the very high incidence of this cancer, upwards of 30,000 men die of prostate cancer each year. The mainstay therapy for recurrent or progressing prostate cancer is androgen deprivation therapy (ADT), which has been in use for almost 80 years. ADT is apparently effective because nearly all prostate cancers are initiated by genetic events that ‘reprogram’ the androgen receptor cistrome, leading to the transcription of gene sets that drive the de-differentiation of prostate epithelial cells, enabling oncogenic transformation. Despite the effectiveness of ADT, this therapy is not curative, and those tumors which can evade ADT are eventually lethal, accounting for the majority of prostate cancer deaths. Thus, there is a need to: i) understand the mechanism of tumor death and recurrence following ADT; ii) identify curative therapies that synergize with or replace ADT; and iii) define the biology of ADT-resistant tumors as a first step to finding effective therapies for these lethal cancers. In this Special Issue, we invite contributions from investigators studying all aspects of the response of prostate cancers to ADT. We are particularly interested in studies that use relevant murine models and human prostate cancer tissue samples or model systems derived from human prostate cancers and consider the response of both tumor cells and the tumor microenvironment, including immune-cell populations.
Dr. John J. Krolewski
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- androgen deprivation therapy
- therapy resistance
- tumor microenvironment
- ADT
